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Introduction {#ehf212652-sec-0005}
============

Acute myocardial infarction with cardiogenic shock (AMI‐CS) remains associated with nearly 30--40% mortality in the contemporary era despite early revascularization.[1](#ehf212652-bib-0001){ref-type="ref"}, [2](#ehf212652-bib-0002){ref-type="ref"}, [3](#ehf212652-bib-0003){ref-type="ref"}, [4](#ehf212652-bib-0004){ref-type="ref"}, [5](#ehf212652-bib-0005){ref-type="ref"}, [6](#ehf212652-bib-0006){ref-type="ref"}, [7](#ehf212652-bib-0007){ref-type="ref"}, [8](#ehf212652-bib-0008){ref-type="ref"}, [9](#ehf212652-bib-0009){ref-type="ref"} AMI‐CS is associated with pump failure and subsequent vasoplegic shock resulting in a complex haemodynamic picture.[5](#ehf212652-bib-0005){ref-type="ref"}, [10](#ehf212652-bib-0010){ref-type="ref"}, [11](#ehf212652-bib-0011){ref-type="ref"}, [12](#ehf212652-bib-0012){ref-type="ref"}, [13](#ehf212652-bib-0013){ref-type="ref"} Given the rapid haemodynamic changes and high vasoactive medication requirements in this population, invasive haemodynamic monitoring with a pulmonary artery catheter (PAC) may have a role in AMI‐CS.[10](#ehf212652-bib-0010){ref-type="ref"}, [14](#ehf212652-bib-0014){ref-type="ref"} There are limited data on the use and outcomes of PAC in AMI‐CS in the contemporary era.[15](#ehf212652-bib-0015){ref-type="ref"}, [16](#ehf212652-bib-0016){ref-type="ref"}, [17](#ehf212652-bib-0017){ref-type="ref"} In 2005, the seminal ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) trial demonstrated no differences in survival and hospitalization outcomes with PAC use in haemodynamically stable patients with heart failure, but this study specifically excluded patients with CS.[18](#ehf212652-bib-0018){ref-type="ref"} Similar studies from the sepsis and acute respiratory distress syndrome literature showed no differences in outcomes with PAC use.[19](#ehf212652-bib-0019){ref-type="ref"} With dissemination of these neutral results, the use of a PAC in undifferentiated shock and critically ill patients has decreased.[20](#ehf212652-bib-0020){ref-type="ref"} However, there are limited epidemiological data on the use of PAC in patients with AMI‐CS, a population not included in these studies. Prior studies from large national databases have focused on only ST elevation or non‐ST elevation populations or alternately have included undifferentiated CS because of a combination of AMI and end‐stage heart failure.[21](#ehf212652-bib-0021){ref-type="ref"}, [22](#ehf212652-bib-0022){ref-type="ref"} Using a 15 year nationally representative database, we sought to assess the use of PAC in AMI‐CS in USA. We also sought to understand the use of right heart catheterization (RHC) that is independent of PAC use in this population.

Methods {#ehf212652-sec-0006}
=======

The Nationwide/National Inpatient Sample (NIS) is the largest all‐payer database of hospitalized inpatients in USA. The NIS contains discharge data from a 20% stratified sample of nonfederal hospitals and is a part of the Healthcare Cost and Utilization Project (HCUP), sponsored by the Agency for Healthcare Research and Quality.[23](#ehf212652-bib-0023){ref-type="ref"} Information regarding each discharge includes patient demographics, primary payer, hospital characteristics, principal diagnosis, up to 24 secondary diagnoses, and procedural diagnoses. The HCUP‐NIS does not capture individual patients but captures all information for a given admission/hospitalization.

Study population, variables, and outcomes {#ehf212652-sec-0007}
-----------------------------------------

Using the HCUP‐NIS data from 2000 to 2014, a retrospective cohort study of admissions with AMI‐CS was identified. AMI in the primary procedure field was identified using International Classification of Diseases 9 Clinical Modification (ICD‐9CM) codes for ST elevation MI (ICD‐9CM 410.1×--410.6×, 410.8×, 410.9×) and non‐ST elevation myocardial infarction (ICD‐9CM 410.×).[24](#ehf212652-bib-0024){ref-type="ref"} CS was identified using ICD‐9CM code 785.51 that has a specificity of 99.3%, sensitivity of 59.8%, positive predictive value of 78.8%, and negative predictive value of 98.1%.[25](#ehf212652-bib-0025){ref-type="ref"} Patients without in‐hospital mortality data and AMI‐CS admissions that underwent cardiac surgery (coronary artery bypass grafting, valve repair, valve replacement, durable left ventricular assist device, and orthotropic heart transplant) were excluded. Consistent with prior data, we identified PAC use using the ICD‐9CM codes 89.63 (pulmonary artery pressure monitoring), 89.64 (pulmonary artery wedge monitoring), 89.66 (measurement of mixed venous blood gases), 89.67 \[monitoring of cardiac output by oxygen consumption technique (Fick method)\], and 89.68 \[monitoring of cardiac output by other technique (thermodilution indicator)\].[22](#ehf212652-bib-0022){ref-type="ref"}, [26](#ehf212652-bib-0026){ref-type="ref"}, [27](#ehf212652-bib-0027){ref-type="ref"} The use of RHC was identified using ICD‐9CM 37.21 and 37.23, which reflect as isolated measurement of pulmonary arterial pressures or concomitant use with a left heart catheterization.[15](#ehf212652-bib-0015){ref-type="ref"} Though it is possible that the RHC was subsequently converted to PAC monitoring, there is no reliable way to assess in the absence of a concomitant code for PAC placement. An exploratory cohort of admissions receiving invasive haemodynamic monitoring (IHDM), that is, RHC and/or PAC was also evaluated. Therefore, the PAC cohort was restricted conservatively to those with an ICD‐9CM for a PAC only. Demographic characteristics, hospital characteristics, acute organ failure, coronary angiography, percutaneous coronary interventions (PCI), and mechanical circulatory support (MCS) use were identified for all admissions using previously used methodologies from our group.[2](#ehf212652-bib-0002){ref-type="ref"}, [3](#ehf212652-bib-0003){ref-type="ref"}, [4](#ehf212652-bib-0004){ref-type="ref"}, [5](#ehf212652-bib-0005){ref-type="ref"}, [8](#ehf212652-bib-0008){ref-type="ref"}, [9](#ehf212652-bib-0009){ref-type="ref"}, [28](#ehf212652-bib-0028){ref-type="ref"}, [29](#ehf212652-bib-0029){ref-type="ref"}, [30](#ehf212652-bib-0030){ref-type="ref"}, [31](#ehf212652-bib-0031){ref-type="ref"}, [32](#ehf212652-bib-0032){ref-type="ref"}, [33](#ehf212652-bib-0033){ref-type="ref"}, [34](#ehf212652-bib-0034){ref-type="ref"}, [35](#ehf212652-bib-0035){ref-type="ref"} Acute noncardiac organ failure was classified as respiratory (acute respiratory failure, other pulmonary insufficiency, acute respiratory distress syndrome, respiratory arrest, and ventilator management), renal (acute kidney injury), and hepatic (acute hepatic failure, hepatic encephalopathy, hepatic infection, and hepatitis unspecified), hematologic (defibrination syndrome, acquired coagulation factor deficiency, coagulation defect, and thrombocytopenia), and neurologic (anoxic brain injury, acute encephalopathy, coma, altered consciousness, and electroencephalogram).[3](#ehf212652-bib-0003){ref-type="ref"}, [4](#ehf212652-bib-0004){ref-type="ref"}, [5](#ehf212652-bib-0005){ref-type="ref"}, [9](#ehf212652-bib-0009){ref-type="ref"}, [30](#ehf212652-bib-0030){ref-type="ref"}, [32](#ehf212652-bib-0032){ref-type="ref"} Similar to prior literature from the HCUP‐NIS, we used the procedure day for RHC/PAC placement to time concomitant coronary angiography, PCI, MCS, and invasive mechanical ventilation.[36](#ehf212652-bib-0036){ref-type="ref"} The Deyo\'s modification of the Charlson comorbidity index was used to identify the burden of co‐morbid diseases (Supporting Information, *Table* [*S1*](#ehf212652-supitem-0001){ref-type="supplementary-material"}).[37](#ehf212652-bib-0037){ref-type="ref"}

The primary outcome was the temporal trends of PAC use during the 15 year study period. Temporal trend analysis was further stratified by patient characteristics, hospital demographics, and in the years before (2000--2006) and after (2007--2014) the ESCAPE trial. Secondary outcomes included timing of PAC placement, use with RHC/PAC with concomitant cardiac procedures, in‐hospital mortality, length of stay, hospitalization costs, and discharge disposition in admissions with and without PAC use. In the cohort without PAC use, we compared clinical outcomes between patients that received and did not receive a RHC. A supplementary analysis was performed for unadjusted and adjusted temporal trends in the use and in‐hospital mortality for all admissions receiving IHDM.

Statistical analysis {#ehf212652-sec-0008}
--------------------

As recommended by HCUP‐NIS, survey procedures using discharge weights provided with HCUP‐NIS database were used to generate national estimates. Using the trend weights provided by the HCUP‐NIS, samples from 2000 to 2011 were re‐weighted to adjust for the 2012 HCUP‐NIS redesign.[38](#ehf212652-bib-0038){ref-type="ref"} χ^2^ and *t*‐tests were used to compare categorical and continuous variables, respectively. Logistic regression was used to analyse trends over time (referent year 2000). The inherent restrictions of the HCUP‐NIS database related to research design, data interpretation, and data analysis were reviewed and addressed.[38](#ehf212652-bib-0038){ref-type="ref"} Univariable analysis for trends and outcomes was performed and was represented as odds ratio (OR) with 95% confidence interval (CI). Multivariable logistic regression analysis incorporating age, sex, race, primary payer status, socio‐economic stratum, hospital characteristics, comorbidities, acute organ failure, AMI type, cardiac procedures, and noncardiac procedures was performed for temporal trends of PAC use, temporal trends of in‐hospital mortality, predictors of PAC use, and in‐hospital mortality. For the multivariable modelling, regression analysis with purposeful selection of statistically (liberal threshold of *P* \< 0.20 in univariate analysis) and clinically relevant variables was conducted.

Multiple confirmatory and subgroup analyses were performed to verify the validity of these findings. We performed a propensity‐matched analysis for patient demographics, comorbidities, hospital characteristics, acute organ failure, and acute care interventions between the two cohorts. For the propensity matching, all variables except race had \<1% missing variables. For the race category, missing variables were treated as a separate category. Using 1:1 nearest neighbour matching, 6200 matching pairs (12 400 individual admissions) were developed for further use. The propensity‐matched sample had standardized differences \<10% for all baseline characteristics. The McNemar χ^2^ test and paired sample *t*‐tests were used to compare categorical and continuous variables, respectively, in the propensity‐matched sample. An additional analysis of outcomes was performed in the cohort that did not receive PAC between the admissions that received a RHC vs. those who did not. An exploratory supplementary analysis of temporal trends and in‐hospital mortality in the cohort receiving IHDM vs. those who did not was performed. Two‐tailed *P* \< 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 25.0 (IBM Corp, Armonk NY).

Results {#ehf212652-sec-0009}
=======

In the period between 1 January 2000 and 31 December 2014, an estimated 9 747 034 admissions for a primary diagnosis of AMI were identified, of which 444 253 (4.6%) developed CS. Of these admissions with AMI‐CS, 80 252 (18.1%) had concomitant cardiac surgery during the hospital admission and were subsequently excluded. In the final cohort of 364 001 admissions, PAC was used in 29 609 (8.1%). Baseline characteristics of the cohorts with and without PAC use are summarized in *Table* [1](#ehf212652-tbl-0001){ref-type="table"}. Admissions that received a PAC had higher rates of prior heart failure (66.5% vs. 53.9%; *P* \< 0.001). During the tertiles of the study period, there was a serial decrease in mean age and increase in comorbidity, proportion of non‐ST segment‐elevation AMI‐CS, and admissions to urban teaching hospitals (*Table* [*S2*](#ehf212652-supitem-0001){ref-type="supplementary-material"}). The 15 year unadjusted and adjusted temporal trends of PAC use (*Figure* [*1*](#ehf212652-fig-0001){ref-type="fig"}) noted a significant decrease in PAC use in AMI‐CS. Temporal trends in the use of PAC stratified by patient and hospital characteristics demonstrated a decrease in temporal use of PAC in AMI‐CS (*Figure* [*2*](#ehf212652-fig-0002){ref-type="fig"}). Greater proportion of admissions to urban teaching hospitals received PACs (9.5%) compared with urban non‐teaching (7.1%) and rural hospitals (5.4%) with a proportionally consistent temporal decline during the study period (*Figure* [*2*](#ehf212652-fig-0002){ref-type="fig"}). Compared with those without PAC use, those with PAC use had a higher prevalence of acute organ failure, pulmonary haemorrhage, and noncardiac organ support (*Table* [2](#ehf212652-tbl-0002){ref-type="table"}). The PAC cohort received more frequent coronary angiography and MCS support but had lower rates of PCI (*Table* [2](#ehf212652-tbl-0002){ref-type="table"}). In a multivariable regression analysis, younger age, male sex, white race, higher comorbidity, noncardiac organ failure, and use of MCS and noncardiac organ support were independent predictors of PAC use (*Table* [3](#ehf212652-tbl-0003){ref-type="table"}).

###### 

Baseline characteristics of acute myocardial infarction‐cardiogenic shock with and without pulmonary artery catheter use

  Characteristic                                     PAC (*N* = 29 609)    No PAC (*N* = 334 392)     *P*    
  -------------------------------------------------- -------------------- ------------------------ --------- ---------
  AMI type                                           ST elevation AMI               70.5             70.4      0.84
  Non‐ST elevation AMI                               29.5                           29.6                     
  Age (years)                                        68.3 ± 12.5                70.1 ± 13.4         \<0.001  
  Female sex                                         37.7                           41.0            \<0.001  
  Race                                               White                          77.8             78.1     \<0.001
  Black                                              6.8                            7.2                      
  Others                                             15.4                           14.7                     
  Weekend admission                                  27.3                           27.6             0.32    
  Primary payer                                      Medicare                       61.1             63.7     \<0.001
  Medicaid                                           6.6                            6.0                      
  Private                                            24.8                           22.5                     
  Uninsured                                          5.0                            5.5                      
  Others                                             2.5                            2.3                      
  Quartile of median household income for zip code   0--25th                        17.6             23.7     \<0.001
  26th--50th                                         24.8                           26.8                     
  51st--75th                                         25.8                           24.9                     
  75th--100th                                        31.8                           24.6                     
  Hospital teaching status and location              Rural                          5.6               8.8     \<0.001
  Urban non‐teaching                                 36.4                           42.3                     
  Urban teaching                                     58.0                           49.0                     
  Hospital bed size                                  Small                          6.6               8.5     \<0.001
  Medium                                             20.1                           23.3                     
  Large                                              73.3                           68.3                     
  Hospital region                                    Northeast                      22.0             18.5     \<0.001
  Midwest                                            21.8                           23.1                     
  South                                              31.0                           38.6                     
  West                                               25.2                           19.7                     
  Charlson comorbidity index                         0--3                           22.8             23.6     \<0.001
  4--6                                               59.5                           54.4                     
  ≥7                                                 17.7                           22.0                     

Represented as percentage or mean ± standard deviation.

![Unadjusted and adjusted 15 year temporal trends of PAC use and in‐hospital mortality in cohorts with and without PAC use in AMI‐CS. Panel (A): Unadjusted temporal trends of PAC use in AMI‐CS (*P* \< 0.001). Panel (B): Adjusted multivariable logistic regression for temporal trends of PAC use with 2000 as referent year; adjusted for age, sex, race, primary payer, socio‐economic status, hospital location/teaching status, hospital bed size, hospital region, comorbidity, acute organ failure, cardiac arrest, coronary angiography, percutaneous coronary intervention, mechanical circulatory support, invasive mechanical ventilation, haemodialysis (*P* \< 0.001); Panel (C): Unadjusted temporal trends of in‐hospital mortality in AMI‐CS stratified by PAC use (*P* \< 0.001); Panel (D): Adjusted multivariable logistic regression for in‐hospital mortality temporal trends with 2000 as referent year; adjusted for age, sex, race, primary payer, socio‐economic status, hospital location/teaching status, hospital bed size, hospital region, comorbidity, acute organ failure, cardiac arrest, coronary angiography, percutaneous coronary intervention, mechanical circulatory support, invasive mechanical ventilation, haemodialysis (*P* \< 0.001). The dotted line demarcates the period before and after the ESCAPE trial. AMI, acute myocardial infarction; CS, cardiogenic shock; PAC, pulmonary artery catheter.](EHF2-7-1234-g001){#ehf212652-fig-0001}

![Temporal trends of PAC use in AMI‐CS stratified by patient and hospital characteristics. Fifteen year temporal trends of PAC use in AMI‐CS stratified by patient age groups (Panel A), sex (Panel B), race (Panel C), and hospital location and teaching status (Panel D), hospital bed size (Panel E), and hospital region (Panel F); (all *P* \< 0.001). The dotted line demarcates the period before and after the ESCAPE trial. AMI, acute myocardial infarction; CS, cardiogenic shock; PAC, pulmonary artery catheter.](EHF2-7-1234-g002){#ehf212652-fig-0002}

###### 

In‐hospital course and management of acute myocardial infarction‐cardiogenic shock with and without pulmonary artery catheter use

  Characteristic                       PAC (*N* = 29 609)    No PAC (*N* = 334 392)     *P*    
  ------------------------------------ -------------------- ------------------------ --------- ---------
  Acute organ dysfunction              Respiratory                    57.6             44.1     \<0.001
  Renal                                43.1                           33.6            \<0.001  
  Hepatic                              10.8                           7.7             \<0.001  
  Pulmonary haemorrhage                1.7                            1.1             \<0.001  
  Cardiac arrest                       18.9                           19.5             0.02    
  Coronary angiography                 70.2                           64.7            \<0.001  
  Percutaneous coronary intervention   48.4                           53.4            \<0.001  
  MCS                                  IABP                           52.8             37.6     \<0.001
  Percutaneous MCS                     2.4                            1.3             \<0.001  
  ECMO                                 0.6                            0.3             \<0.001  
  Invasive mechanical ventilation      61.4                           42.1            \<0.001  
  Haemodialysis                        5.8                            2.9             \<0.001  

Represented as percentage.

ECMO, extracorporeal membrane oxygenation; IABP, intra‐aortic balloon pump; MCS, mechanical circulatory support.

###### 

Multivariable regression for predictors of pulmonary artery catheter use in acute myocardial infarction‐cardiogenic shock

  Total cohort (*N* = 364 001)                       Odds ratio     95% confidence interval   *P*             
  -------------------------------------------------- ------------- ------------------------- ------ --------- ---------
  Age groups (years)                                 19--49           Reference category                      
  50--59                                             0.93                    0.88             0.99    0.02    
  60--69                                             0.88                    0.83             0.94   \<0.001  
  70--79                                             0.87                    0.82             0.93   \<0.001  
  ≥80                                                0.64                    0.60             0.69   \<0.001  
  Female sex                                         0.97                    0.94             0.99    0.009   
  Race                                               White            Reference category                      
  Non‐white                                          0.96                    0.93             0.99    0.002   
  Primary payer                                      Medicare         Reference category                      
  Medicaid                                           0.94                    0.89             0.99    0.03    
  Private                                            0.98                    0.94             1.02    0.26    
  Uninsured                                          0.86                    0.80             0.91   \<0.001  
  No charge                                          1.10                    0.91             1.34    0.32    
  Others                                             1.04                    0.96             1.12    0.39    
  Quartile of median household income for zip code   0--25th          Reference category                      
  26th--50th                                         1.25                    1.20             1.29   \<0.001  
  51st--75th                                         1.35                    1.29             1.40   \<0.001  
  75th--100th                                        1.60                    1.54             1.67   \<0.001  
  Weekend admission                                  1.00                    0.98             1.02    0.85    
  Hospital teaching status and location              Rural            Reference category                      
  Urban non‐teaching                                 0.97                    0.92             1.03    0.34    
  Urban teaching                                     1.32                    1.25             1.40   \<0.001  
  Hospital bed size                                  Small            Reference category                      
  Medium                                             1.09                    1.03             1.15    0.001   
  Large                                              1.36                    1.29             1.43   \<0.001  
  Hospital region                                    Northeast        Reference category                      
  Midwest                                            0.88                    0.85             0.92   \<0.001  
  South                                              0.82                    0.79             0.85   \<0.001  
  West                                               1.25                    1.20             1.30   \<0.001  
  Charlson comorbidity index                         0--3             Reference category                      
  4--6                                               1.17                    1.12             1.22   \<0.001  
  ≥7                                                 0.95                    0.90             1.00    0.04    
  Acute organ failure                                Respiratory             1.18             1.15    1.22     \<0.001
  Renal                                              1.29                    1.26             1.33   \<0.001  
  Hepatic                                            1.02                    0.97             1.06    0.50    
  Hematologic                                        1.39                    1.33             1.44   \<0.001  
  Neurologic                                         0.71                    0.69             0.74   \<0.001  
  Cardiac arrest                                     0.80                    0.77             0.83   \<0.001  
  Coronary angiography                               1.24                    1.19             1.28   \<0.001  
  Percutaneous coronary intervention                 0.54                    0.52             0.56   \<0.001  
  Mechanical circulatory support                     1.94                    1.88             1.99   \<0.001  
  Invasive mechanical ventilation                    1.84                    1.79             1.90   \<0.001  
  Haemodialysis                                      1.28                    1.20             1.35   \<0.001  

Compared with those without PAC use, the cohort with PAC use had higher unadjusted in‐hospital all‐cause mortality (42% vs. 46.3%; OR 1.19 \[95% CI 1.16--1.22\]; *P* \< 0.001). The 15 year unadjusted and adjusted temporal trends of in‐hospital mortality are presented in *Figure* [*1*](#ehf212652-fig-0001){ref-type="fig"} *C* and [*1*](#ehf212652-fig-0001){ref-type="fig"} *D*. Admissions with PAC use had a longer length of stay (10.9 ± 10.9 vs. 8.2 ± 9.3 days), higher hospitalization costs (\$128 247 ± 138 181 vs. \$96 509 ± 116 060), and less frequent discharges to home (36.3% vs. 46.4%) compared with the cohort that did not receive a PAC (all *P* \< 0.001). In a multivariable logistic regression analysis, PAC use (OR 1.07 \[95% CI 1.04--1.10\]; *P* \< 0.001) was independently associated with higher in‐hospital mortality in AMI‐CS (Table [S3](#ehf212652-supitem-0001){ref-type="supplementary-material"}). Using a 1:1 propensity‐matching analysis, 12 400 admissions (6200 pairs) were evaluated (*Table* [*S4*](#ehf212652-supitem-0001){ref-type="supplementary-material"}). In the propensity‐matched sample, there were no differences in in‐hospital mortality in the cohorts with and without PAC use (46.4% vs. 46.2%; OR 1.01 \[95% CI 0.94--1.08\]; *P* = 0.84). The propensity‐matched cohort receiving PAC was discharged home less frequently (19.5% vs. 23.1%), had longer length of hospital stay (10.8 ± 10.9 vs. 10.4 ± 9.7 days), and had higher hospitalization costs (\$137 660 ± 127 881 vs. 131 546 ± 113 261) (all *P* \< 0.001).

In the cohort that did not receive a PAC (*N* = 334 392), a RHC was performed in 41 719 (12.5%) admissions. Compared with those without a RHC, those who received a RHC were younger, more often male sex, of non‐white race, with lower comorbidity, and higher acuity of illness (*Table* [*S5*](#ehf212652-supitem-0001){ref-type="supplementary-material"}). Admissions receiving a RHC had higher use of PCI, MCS, and noncardiac organ support. The RHC cohort had lower unadjusted (35.5% vs. 43%; OR 0.73 \[95% CI 0.72--0.75\]; *P* \< 0.001) in‐hospital mortality but not adjusted in‐hospital mortality (OR 1.01 \[95% CI 0.99--1.04\]; *P* = 0.38). The cohort with RHC use had longer hospital stay and higher hospitalization costs compared with those without a RHC (*Table* [*S6*](#ehf212652-supitem-0001){ref-type="supplementary-material"}). Temporal trends in the use and in‐hospital mortality in the cohorts with and without IHDM (RHC and/or PAC) showed trends similar to those with PAC use (*Figure* [*S1*](#ehf212652-supitem-0002){ref-type="supplementary-material"}). The cohort that received IHDM had lower in‐hospital mortality than those without IHDM on unadjusted analyses but not on adjusted analyses (40% vs. 43%; unadjusted OR 0.88 \[95% CI 0.87--0.90\]; *P* \< 0.001; adjusted OR 1.01 \[95% CI 0.98--1.05; *P* = 0.73) (adjusted for covariates listed in *Table* [*S3*](#ehf212652-supitem-0001){ref-type="supplementary-material"}).

The timing of PAC/RHC placement was available for 53 247 (74.7%) of the total cohort. RHC/PAC was performed at a median of 0 (interquartile range 0--1) days after admission, with 63% performed the day of admission (*Figure* [*3*](#ehf212652-fig-0003){ref-type="fig"} *A*). RHC/PAC was performed concomitantly with coronary angiography, PCI, MCS, and invasive mechanical ventilation in 11.2%, 7.1%, 7.7%, and 5.3% admissions, respectively. In the total cohort, 5.3% of the admissions received coronary angiography (with/without PCI), MCS, and PAC on the same day (*Figure* [*3*](#ehf212652-fig-0003){ref-type="fig"} *B*).

![Timing of PAC placement and concomitant cardiac procedures in AMI‐CS. Panel (A): Timing of RHC/PAC during hospital stay (percentage); Panel (B): Fifteen year temporal trends of PAC with concomitant cardiac and noncardiac procedures. The dotted line demarcates the period before and after the ESCAPE trial. AMI, acute myocardial infarction; CA, coronary angiography; CS, cardiogenic shock; IMV, invasive mechanical ventilation; MCS, mechanical circulatory support; PAC, pulmonary artery catheter; PCI, percutaneous coronary intervention; RHC, right heart catheterization.](EHF2-7-1234-g003){#ehf212652-fig-0003}

Discussion {#ehf212652-sec-0010}
==========

In this nationally representative population of AMI‐CS, we noted a 75% decrease in PAC use between 2000 and 2014 despite a concomitant increase in patient acuity. Younger age, male sex, white race, higher baseline comorbidity, presence of noncardiac organ failure, and use of MCS were independent predictors of PAC use. Admissions receiving a PAC were a higher risk cohort that had higher unadjusted and adjusted in‐hospital mortality, though these differences were not noted in the propensity‐matched sample. The use of a RHC in admissions that did not receive a PAC was a marker of greater acuity and associated with higher resource utilization but no differences in in‐hospital mortality. About 63% of the RHC/PACs were performed on the admission day with nearly 13% performed on the same day as coronary angiography, PCI, MCS, or invasive mechanical ventilation.

This study provides novel insight into management and outcome of a population not previously evaluated. In patients with ST elevation AMI‐CS, Kolte et al.[39](#ehf212652-bib-0039){ref-type="ref"} noted a declining trend in the use of PAC during 2003--2010. Consistent with these data, we note a similar trend in all AMI‐CS patients over a longer study period (2000--2014). Furthermore, this current study evaluates the use of RHC, either concomitantly with coronary angiography and MCS or in isolation, providing further insights into management of this complex population. The RHC provides similar information without the need for prolonged monitoring; however, the relative role both modalities needs further evaluation. Hernandez et al.[22](#ehf212652-bib-0022){ref-type="ref"} noted decreased mortality in the CS admissions because of end‐stage heart failure receiving a PAC. In contrast to their data, our study did not observe a similar signal.[7](#ehf212652-bib-0007){ref-type="ref"}, [40](#ehf212652-bib-0040){ref-type="ref"} Patients with end‐stage heart failure typically have higher filling pressures, lower ejection fractions, but with lesser end‐organ hypoperfusion that is likely related to the chronicity of the process.[40](#ehf212652-bib-0040){ref-type="ref"} These differences may justify the greater benefit of PAC in the end‐stage heart failure population to aid in close optimization of filling pressures and fluid status. The results of our study can be readily compared with the substudy from GUSTO IIb and III (Global Use of Strategies To Open occluded coronary arteries in acute coronary syndromes) trials.[41](#ehf212652-bib-0041){ref-type="ref"} In this study, the cohort with PACs more frequently received coronary revascularization, mechanical circulatory support, and mechanical ventilation consistent with our data. These patients had higher resource utilization and short‐term mortality in the unmatched cohort and higher resource utilization in the propensity‐matched cohort, suggesting that PAC use is a marker for greater illness severity.[41](#ehf212652-bib-0041){ref-type="ref"}, [42](#ehf212652-bib-0042){ref-type="ref"} As noted in our study, in admissions within the non‐PAC cohort, RHC was used in those with greater severity, without any differences in outcomes. Smaller studies have shown the use of a PAC to be associated with improved survival in CS because of any aetiology.[43](#ehf212652-bib-0043){ref-type="ref"}, [44](#ehf212652-bib-0044){ref-type="ref"} Rossello et al.[16](#ehf212652-bib-0016){ref-type="ref"} showed the use of PAC to be associated with lower mortality in CS from non‐AMI aetiology, but no differences in those with AMI‐CS. In a subgroup analysis of the CardShock study, Sionis et al.[17](#ehf212652-bib-0017){ref-type="ref"} noted the use of a PAC to be associated with greater use of aggressive therapies (including inotropes) but without any differences in in‐hospital mortality.

This study noted a declining trend in the use of PAC in AMI‐CS, which is in contrast to similar studies from patients with heart failure.[26](#ehf212652-bib-0026){ref-type="ref"}, [45](#ehf212652-bib-0045){ref-type="ref"} These rates of decline started before the ESCAPE trial and continued to show a steady downward trend. These trends of declining PAC use were consistent across all patient and hospital characteristics as noted in a prior study in Medicare beneficiaries with AMI.[46](#ehf212652-bib-0046){ref-type="ref"} The use of PAC in this study is lower than that noted in prospective registries of patients with AMI‐CS.[17](#ehf212652-bib-0017){ref-type="ref"}, [43](#ehf212652-bib-0043){ref-type="ref"} This may be postulated to be because of lesser severity of CS in this nationally representative population, multiple neutral trials in both cardiac and noncardiac patients, the ubiquitous use of echocardiography, and advances in non‐invasive/minimally invasive haemodynamic monitoring.[20](#ehf212652-bib-0020){ref-type="ref"}, [41](#ehf212652-bib-0041){ref-type="ref"} This study also identified unique predictors of PAC use. Presence of noncardiac organ failure and use of invasive mechanical ventilation and haemodialysis were strong predictors of PAC use in AMI‐CS. This can be hypothesized to be because of the development of complex haemodynamics in this population with superimposed distributive shock, which needs careful understanding of cardiac haemodynamics and titration of vasoactive medications.[10](#ehf212652-bib-0010){ref-type="ref"}, [12](#ehf212652-bib-0012){ref-type="ref"}, [13](#ehf212652-bib-0013){ref-type="ref"} This study noted significant disparities in the use of PAC in this nationally representative population. We noted greater use of PAC in admissions with higher socio‐economic status and bearing insurance coverage, which may allude to social disparities noted in other AMI populations.[47](#ehf212652-bib-0047){ref-type="ref"}, [48](#ehf212652-bib-0048){ref-type="ref"} Furthermore, the use of PAC in large urban hospitals and in patients with MCS demonstrates the paradigm shift in the management of AMI‐CS with the advent of newer percutaneous MCS devices.[15](#ehf212652-bib-0015){ref-type="ref"}, [43](#ehf212652-bib-0043){ref-type="ref"}, [49](#ehf212652-bib-0049){ref-type="ref"}, [50](#ehf212652-bib-0050){ref-type="ref"} Second, with advanced MCS being available in the contemporary era,[6](#ehf212652-bib-0006){ref-type="ref"}, [7](#ehf212652-bib-0007){ref-type="ref"}, [28](#ehf212652-bib-0028){ref-type="ref"}, [29](#ehf212652-bib-0029){ref-type="ref"}, [51](#ehf212652-bib-0051){ref-type="ref"}, [52](#ehf212652-bib-0052){ref-type="ref"}, [53](#ehf212652-bib-0053){ref-type="ref"} PAC is being increasingly used to treat patients with higher severity of illness.[15](#ehf212652-bib-0015){ref-type="ref"}, [45](#ehf212652-bib-0045){ref-type="ref"} Preliminary data have shown improvements in clinical outcomes with a protocoled approached to AMI‐CS including the use of PAC.[54](#ehf212652-bib-0054){ref-type="ref"}, [55](#ehf212652-bib-0055){ref-type="ref"} This is substantiated by the use of greater cardiac and noncardiac organ support in our study and the higher use of MCS and PACs in large, urban teaching hospitals.[28](#ehf212652-bib-0028){ref-type="ref"}, [29](#ehf212652-bib-0029){ref-type="ref"} There exist significant disparities in the hospital‐level management and outcomes of AMI‐CS.[2](#ehf212652-bib-0002){ref-type="ref"} It is possible that these disparities may contribute to the higher use of PAC at large, urban teaching hospitals, or alternately this is representative of the higher acuity of illness in these centres. This crucial selection bias has been previously validated in the ESCAPE registry that noted greater PAC use in heart failure patients with higher severity of illness.[56](#ehf212652-bib-0056){ref-type="ref"}

In this study, we noted nearly 63% of RHC/PAC performed on admission with 13% performed concomitantly with other cardiac and noncardiac procedures. Nalluri et al.[15](#ehf212652-bib-0015){ref-type="ref"} noted the use of a RHC in AMI‐CS admissions receiving percutaneous MCS to be associated with lower in‐hospital mortality. It is important to note that this study specifically studied RHC with/without concomitant PAC use, because it sought to capture the use of RHC simultaneously with MCS placement. In contrast to their work, this study did not demonstrate any survival benefit from RHC use in the non‐PAC population. The use of RHC/PAC‐derived variables such as cardiac power output (mean arterial pressure X cardiac output/451) has shown significant survival correlations and remains worthy of further dedicated study.[43](#ehf212652-bib-0043){ref-type="ref"}, [57](#ehf212652-bib-0057){ref-type="ref"}

Limitations {#ehf212652-sec-0011}
-----------

This study has several limitations, despite the HCUP‐NIS database\'s attempts to mitigate potential errors by using internal and external quality control measures. The ICD‐9CM codes for AMI and CS have been previously validated, reducing the inherent errors in ascertainment in this study.[24](#ehf212652-bib-0024){ref-type="ref"}, [25](#ehf212652-bib-0025){ref-type="ref"}, [27](#ehf212652-bib-0027){ref-type="ref"} However, as noted in the Methods section, the validation study for CS shows moderate sensitivity, and therefore, this study may have missed some admissions with CS. Although we used a strategy consistent with prior work from administrative databases,[22](#ehf212652-bib-0022){ref-type="ref"}, [26](#ehf212652-bib-0026){ref-type="ref"}, [27](#ehf212652-bib-0027){ref-type="ref"} the ICD‐9CM codes for PAC have not been formally validated previously. The clinical consequences of using a haemodynamic tool such as the PAC could not be accurately measured, including data interpretation and treatment changes. Because of the administrative nature of this cohort, we do not have haemodynamic data, biventricular function, pulmonary hypertension, and quantification of vasoactive medications; all of which are known to influence outcomes in patients with shock.[12](#ehf212652-bib-0012){ref-type="ref"}, [58](#ehf212652-bib-0058){ref-type="ref"}, [59](#ehf212652-bib-0059){ref-type="ref"}, [60](#ehf212652-bib-0060){ref-type="ref"}, [61](#ehf212652-bib-0061){ref-type="ref"}, [62](#ehf212652-bib-0062){ref-type="ref"}, [63](#ehf212652-bib-0063){ref-type="ref"} The declining use of the PAC may have resulted in consequent hesitation in using and/or challenges with interpretation of information.[20](#ehf212652-bib-0020){ref-type="ref"} The ICD‐9CM codes for a RHC are not validated, and it is possible that those receiving a RHC had a PAC left *in situ* for continuous monitoring. Admissions receiving durable cardiac replacement therapy such as left ventricular assist devices and cardiac transplantation were excluded from this study, and therefore, our data cannot be extrapolated to this population. The HCUP‐NIS does not provide information on level of care (intensive care unit, step‐down unit, or floor level), so we cannot evaluate the influence of specialized care on the outcomes in this population. Despite these limitations, this study addresses an important knowledge gap highlighting the epidemiology of PAC use in AMI‐CS in a contemporary 15 year period.

Conclusions {#ehf212652-sec-0012}
===========

In this large study of 364 001 AMI‐CS admissions, these observational data suggest a 75% decrease in PAC use between 2000 and 2014. Use of a PAC identified a higher risk cohort with greater organ failure and higher in‐hospital mortality and resource utilization. Further research is needed on the role of PAC use in the acute management of AMI‐CS in light to aid in appropriate haemodynamic optimization in this acutely ill cohort.[7](#ehf212652-bib-0007){ref-type="ref"}, [49](#ehf212652-bib-0049){ref-type="ref"}
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